profit from every $100 of sales.
$0$100
Ernexa Therapeutics
$2.05+9.04% today
-95.3% in 1 year
1-year low $1.831-year high $43.75
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2024.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Ernexa Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$14.1 million of profit last year.
SalesProfit
Ernexa Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ernexa Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Ernexa Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 0 | |
| 0 | -0 | 0 | 0 | |
| -27 | -21 | -17 | -9 | |
| -24 | -20 | -36 | -14 | |
| -25 | -22 | -45 | -14 | |
| -3,022.50 | -1,530.00 | -1,224.00 | -56.00 | |
| – | -247.1% | 83.5% | – | |
| – | -30,404.4% | -2,963.9% | – | |
| – | -31,864.7% | -7,652.7% | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 22 | 49 | 5 | 6 |
| Cash | 11 | 8 | 2 | 2 |
| Total debt | 1 | 42 | 1 | 0 |
| Total liabilities | 10 | 47 | 4 | 3 |
| 12 | 2 | 2 | 2 | |
| 0 | 0 | 0 | 0 | |
| -145.7% | -37.7% | -1,250.7% | -385.4% | |
| -203.0% | -970.4% | -2,618.4% | -586.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -21 | -20 | -16 | -7 | |
| 0 | 0 | 0 | 0 | |
| -21 | -20 | -16 | -7 | |
| Dividends paid | 0 | 0 | 0 | – |
| – | – | – | – | |
| 3 | 1 | 2 | 1 |
Valuation
- –
- –
- –
- 1.6×
- 5.7×
- –
- –
- -484.2%
- -1,330.9%
- 0.0%
Profitability
- 83.5%
- -2,963.9%
- -7,652.7%
- 0.0%
- -138.7%
- -597.8%
- -263.7%
- -108.0%
- -143.0%
- –
Growth
- +755.9%
- –
- +56.5%
- –
- +30.6%
Financial health
- -0.0×
- 0.06
- 3.7%
- -326.9×
- 2.89
- 2.89
- 0.00
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -6.95 | -1.95 | −256.4% |
| Mar 13, 2026 | -0.25 | – | – |
| Nov 7, 2025 | -0.15 | -33.00 | +99.5% |
| Aug 13, 2025 | -0.61 | -39.00 | +98.4% |
| May 7, 2025 | -2.25 | -48.00 | +95.3% |
| Mar 13, 2025 | -48.00 | -37.50 | −28.0% |
| Nov 12, 2024 | -0.74 | -0.24 | −207.3% |
| Aug 13, 2024 | -15.29 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
64Pass
Philip Fisher
52No pass
Peter Lynch
11No pass
Joel Greenblatt
2No pass
Charlie Munger
50No pass
Terry Smith
40No pass
Questions about Ernexa Therapeutics
Is Ernexa Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ernexa Therapeutics AI analysis
What does Ernexa Therapeutics do?
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. It is in Biotechnology.
Does Ernexa Therapeutics pay a dividend?
No. Ernexa Therapeutics does not pay a dividend at the moment.
Is Ernexa Therapeutics stock halal?
No. Ernexa Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 56% of its market value, at or above the 33% limit. How we check
How has Ernexa Therapeutics stock done over the past year?
Down 95.3% over the past twelve months, to $2.05. It traded between $1.83 and $43.75 and is 95.3% below its high.
Who are Ernexa Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Ernexa Therapeutics's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.